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Nicotinamide adenine dinucleotide phosphate (NAPDH) oxidase (NOX) is an enzyme
complex with the sole function of producing superoxide anion and reactive oxygen
species (ROS) at the expense of NADPH. Vital to the immune system as well as cellular
signaling, NOX is also involved in the pathologies of a wide variety of disease states.
Particularly, it is an integral player in many neurological diseases, including stroke, TBI,
and neurodegenerative diseases. Pathologically, NOX produces an excessive amount
of ROS that exceed the body’s antioxidant ability to neutralize them, leading to oxidative
stress and aberrant signaling. This prevalence makes it an attractive therapeutic target
and as such, NOX inhibitors have been studied and developed to counter NOX’s
deleterious effects. However, recent studies of NOX have created a better understanding
of the NOX complex. Comprised of independent cytosolic subunits, p47-phox, p67-
phox, p40-phox and Rac, and membrane subunits, gp91-phox and p22-phox, the
NOX complex requires a unique activation process through subunit interaction. Of these
subunits, p47-phox plays the most important role in activation, binding and translocating
the cytosolic subunits to the membrane and anchoring to p22-phox to organize the
complex for NOX activation and function. Moreover, these interactions, particularly
that between p47-phox and p22-phox, are dependent on phosphorylation initiated by
upstream processes involving protein kinase C (PKC). This review will look at these
interactions between subunits and with PKC. It will focus on the interaction involving
p47-phox with p22-phox, key in bringing the cytosolic subunits to the membrane.
Furthermore, the implication of these interactions as a target for NOX inhibitors such
as apocynin will be discussed as a potential avenue for further investigation, in order
to develop more specific NOX inhibitors based on the inhibition of NOX assembly and
activation.
Keywords: NAPDH oxidase, NOX inhibitors, reactive oxygen species, stroke, ischemia/reperfusion,
neurodegenerative disease, TBI, PKC
INTRODUCTION
Reactive oxygen species (ROS) have been identified as essential players in an increasing number of
disease states, exacerbating oxidative stress and facilitating tissue dysfunction. However, the origin
of ROS varies widely. They originate from both exogenous sources, such as radiation or drugs, and
endogenous sources, including mitochondria, peroxisomes, and a host of enzymes which include
xanthine oxidase, nitric oxide synthetase, p450 cytochrome, and most importantly, nicotinamide
adenine dinucleotide phosphate (NADPH) oxidase (NOX) (Brieger et al., 2012). Of these, NOX is
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the only one with the exclusive role in producing ROS and is the
fundamental source of ROS in our body.
NOX is a family of integral enzyme complexes present
prevalently throughout the body. Classically known for its role in
phagocytic leukocytes, NOX generates superoxide anion (O2•− )
frommolecular oxygen at the expense of NADPHwhen activated
in these cells in order to destroy phagocytosed organisms and
facilitate their anti-microbial function. However, its presence
is not limited to leukocytes but has also been found in most
tissues of the body. Its production of ROS has also been
implicated in biosignaling and cell function as well as in apoptotic
regulation (Sumimoto et al., 2005; D’Autréaux and Toledano,
2007). To prevent ROS overproduction, NOX activation is
heavily modulated through its activation via phosphorylation.
Such phosphorylation is facilitated by stimuli such as activation
via phagocytic particles or by physiological or pathological
cues, particularly cellular stresses (Jiang et al., 2011). These
cues include altered nutritional status, such as hyperglycemia
which can lead to protein kinase C (PKC)-activated NOX
activation, altered cellular environments, such as hypoxia,
and altered chemical environments due to inflammatory and
stressed states (Jiang et al., 2011; Shao and Bayraktutan,
2014).
Beyond its role in defense and signaling, NOX is a primary
player in oxidative stress, the condition where ROS levels
exceed the body’s antioxidant defense mechanisms. With
uncompensated increases in ROS, increases in lipid peroxidation,
cell death, matrix metalloprotease (MMP) production, DNA
damage and deleterious signaling cascades ensue. Such
pathologic production of ROS can lead to a host of disease
states. Excessive NOX production of ROS as well as upregulation
of NOX is seen in numerous disease states, including those
involving inflammation, diabetes, and cancer (Tang et al., 2012).
Moreover, it plays a key role in neurological pathologies. As
a main producer of ROS within the central nervous system
(CNS), NOX contributes greatly to subsequent brain damage
resulting from traumatic brain injury, ischemia/reperfusion
injury in stroke, and to the pathologies of neurodegenerative
diseases (Tang et al., 2011). As a result of its pervasive action,
NOX has become an attractive target for therapies and drugs,
but understanding its assembly and activation process is
critical to developing therapeutic systems with appropriate
specificity.
NOX STRUCTURE, SUBUNIT
INTERACTIONS, AND ACTIVATION
Structure and Subunits
With its prevalence in disease, it is important to characterize
NOX in its structure. The classical NOX found in neutrophils
is an enzyme complex that is comprised of several subunits,
including two membrane subunits (gp91-phox (NOX2) and
p22-phox), three cytosolic subunits (p47-phox, p67-phox,
p40-phox), and the G-protein Rac (Figure 1). More recently,
several NOX complexes have been found with homologs of the
gp91-phox (NOX2) subunit, which are NOX1, NOX3 to NOX5,
DUOX1, and DUOX2. The enzyme complexes take the name of
their catalytic homolog. These alternative subunits have unique
roles in their respective NOX complexes and will be discussed
below.
The NOX complex itself is split between the membrane
compartment and the cytosolic compartment at rest. The
membrane compartment forms the catalytic core of NOX, the
flavocytochrome b558. In the classical NOX complex, this is
comprised of the gp91-phox subunit (NOX2) and p22-phox.
The gp91-phox subunit is the main catalytic subunit that
transfers NADPH electrons via FAD and heme to molecular
oxygen through coupled redox reactions, producing superoxide
anion. It constitutively forms a heterodimer with p22-phox
on the membrane (Yu et al., 1998). However, activation is
dependent on the translocation of the cytosolic subunits to the
membrane subunits as well as independent activation of Rac to
fully assemble the complex. The cytosolic subunits depend on
phosphorylation for activation. At rest, p40-phox and p67-phox
subunits are commonly complexed in the cytosol and may
be associated with p47-phox as well. Phosphorylation activates
p47-phox and unmasks a region to allow it to definitely bind
p67-phox and form a trimeric cytosolic complex (Tsunawaki
and Yoshikawa, 2000; Lapouge et al., 2002). Subsequently,
p47-phox facilitates their translocation to themembrane, binding
primarily to p22-phox and assembling the active NOX complex
(Ago et al., 2003). Though a complex process, this unique
activation process allows for specific modulation at many levels
of the NOX complex both prior to activation and in the
active state (Groemping and Rittinger, 2005; Sumimoto et al.,
2005).
With seven different isoforms, NOX may contain homologs
instead of the gp91-phox (NOX2) subunit. As the catalytic
core of NOX, catalytic function is preserved through structural
homology within these homologs NOX1, NOX 3–5, DUOX1,
and DUOX2. All have six or seven transmembrane domains,
with two heme binding regions containing histidine residues
and a NADPH binding region on the intracellular C-terminus
to facilitate superoxide production. However, regulation,
localization, and function differ slightly across the isoforms.
NOX1 is commonly found in the colon, vascular smooth
muscle cells, and the stomach (Sumimoto et al., 2005). It is
constitutively active due to the subunits with which it interacts.
It is found with the homologs NOXO1 and NOXA1 rather than
p47-phox and p67-phox, respectively, which contribute to its
constitutive activity, as unlike p47-phox, NOXO1 does not need
phosphorylation to translocate to and activate NOX1 (Takeya
et al., 2003; Sumimoto et al., 2005). Aside from phagocytic cells,
including microglia, NOX2 is also found in endothelial cells
and neurons. NOX3 is mainly in fetal tissues of the kidney and
liver. It is also implicated in the development of otoconia in the
inner ear of mice and is localized to adult cochlear and vestibular
systems of the inner ear (Bánfi et al., 2004). Its presence in the
human ear has yet to be established. NOX4 is localized to the
kidneys, cardiovascular endothelial cells and many other cells, as
it is also constitutively active. It does not need cytosolic subunits
for activation, though they are able to modulate NOX4 activity.
It also produces hydrogen peroxide rather than superoxide
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FIGURE 1 | The nicotinamide adenine dinucleotide phosphate (NAPDH) oxidase (NOX) complex and its subunits are shown above with details
pertaining to its activation sequence. The NOX complex consists of two membrane subunits (gp91-phox, or its homologs, and p22-phox) that form the catalytic
core of NOX, several cytosolic subunits (p47-phox, p67-phox, p40-phox (not shown)), and the G-protein Rac, which are required for assembly and activation. In NOX
activation, stimuli induce Protein Kinase C (PKC) activation, which phosphorylates p47-phox, already complexed to p67-phox, and reveals the p47-phox
SH3 domain. The cytosolic subunits then translocate to the membrane due to interactions between the SH3 domains of p47-phox with the proline rich region of
p22-phox. Rac independently translocates to the complex to activate NOX. When activated, NOX produces superoxide ion through a redox reaction with molecular
oxygen and NADPH. The latter is produced from glucose, which enters the cell and as an intermediate of glycolysis, produces glucose-6-phosphate (G-6-P). This
substrate may continue through glycolysis or may be shunted to the hexose monophosphate shunt to produce NADPH by reducing NADP+. The remaining carbon
backbone is shunted back to the glycolytic process downstream of G-6-P to fructose-6-phosphate (F-6-P) and then enters the tricarboxylic acid (TCA) cycle and
electron transport chain to produce energy as adenosine triphosphate (ATP) in mitochondria. However, the NADPH produced, with molecular oxygen, acts as a
substrate for NOX to produce reactive oxygen species (ROS). In disease states, ROS overproduction leads to cell death. NOX inhibitors targeted to prevent this are
also shown with their location of action. NOX inhibition can function through several pathways: (1) By acting on NOX via an unspecified mechanism; (2) By acting on
the PKC isoforms or upstream to PKC to prevent NOX activation by inhibiting phosphorylation; (3) By inhibiting the interactions of p47-phox with NOX subunits,
particularly p22-phox, preventing NOX activation by inhibiting assembly; (4) By acting directly on gp91-phox or its homologs, preventing NOX catalytic activity; and
(5) By preventing Rac translocation to the NOX complex to prevent NOX activation.
anion as its product. NOX1–4 depend on complexing with the
p22-phox subunit and NOX1–3 depend on cytosolic subunits
to function. NOX5, found in lymphocytes of the spleen and
lymph nodes and in the testes, does not need p22-phox to
function and has a calcium-dependent activation mechanism
facilitated via additional EF-hand motifs in its structure.
DUOX1 and 2, dual oxidases, similarly have EF-hand motifs
and subsequently, calcium-dependent activation. However,
they also have a peroxidase-like ectodomain and are mainly
localized to thyrocytes (Sumimoto et al., 2005). With such
variety in structure, regulation, activation and localization, the
different NOX complex isoforms have differing roles across
disease states. Interestingly, however, the NOX2 isoform has
been greatly implicated in most diseases due to its association
with inflammatory cells migrating to disease sites.
p47-phox and p22-phox
Of the NOX subunits, p47-phox plays a central role as the
organizer and translocator of the subunits for activation. It
targets the cytosolic subunits to the membrane via association
with p22-phox. In several NOX isoforms, it is integral in
facilitating NOX activation and function. While the other
components (p67-phox, p40-phox, gp91-phox, and Rac) are also
important in NOX function, their role in NOX assembly and
activation is limited, and thus, will not be elucidated further in
this review. The function of p47-phox is enabled by its structure,
with two adjacent src-homology 3 (SH3) domains, a polybasic
region c-terminal to them, a proline rich region, and a PX (phox)
domain for interactions. The proline rich region binds p67-phox
while the SH3 domains of p47-phox interact with proline rich
regions of p22-phox to create the complex (DeLeo et al., 1995;
Huang and Kleinberg, 1999). However, in the resting state, p47-
phox SH3 domains are hidden due to internal interactions with
a polybasic region C-terminal to the SH3 domains, stretching
from residues 286 to 340 (Leusen et al., 1996; Ago et al.,
1999; Huang and Kleinberg, 1999). This internal interaction
basally inhibits NOX activation by preventing the translocation
of the cytosolic subunits to the flavocytochrome b558 (Ago
et al., 1999). The autoinhibited region is unmasked through
phosphorylation of several key residues in the C-terminus region
from Ser303 to Ser379, inducing a conformational change that
disrupts the SH3 domain and C-terminus internal binding and
allowing for translocation and binding to the phosphorylated
p22-phox (Faust et al., 1995; Leusen et al., 1996; Ago et al., 1999;
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Huang and Kleinberg, 1999; Sumimoto, 2008). Its structure
forms a highly regulated and interactive subunit, reflecting its
role as the main organizer of NOX.
The p22-phox subunit, the target subunit of p47-phox, has
195 amino acids with hydrophobic helices in its N-terminus
anchoring it to the membrane. It is constitutively associated
with gp91-phox or its analog in NOX1 to NOX4 to anchor the
membrane subunits. Structurally, it contains a proline rich region
in its C-terminal tail stretching from residues 149 to 162 that
binds to the SH3 domains on the p47-phox subunit to allow
for the necessary interactions for NOX activation (Leusen et al.,
1996). The interaction between the two subunits will be further
elucidated below.
NOX Activation Through Phosphorylation
by Protein Kinase C (PKC)
Phosphorylation is a vital part of NOX activation in all
NOX isoforms at various stages of activation, even in
constitutively active forms. However, subunit phosphorylation is
necessary for activation in NOX1 to NOX3. In those isoforms,
phosphorylation of p47-phox is of particular interest in order
to uncover its SH3 domains and facilitate translocation of
the cytosolic subunits for activation. However, the mechanism
of phosphorylation provides potential for further therapeutic
targets and elucidates mechanisms through which disease states
potentially progress. Phosphorylation of p47-phox may occur
through several pathways involving serine kinases, including
through PKC isoforms (δ, β, α, ζ), mitogen-activated protein
kinases (MAPK), cAMP dependent kinases, p21-activated
kinases (PAK), and PKB/AKT (Leusen et al., 1996; Groemping
and Rittinger, 2005). However, a primary pathway implicates
PKC isoforms in its phosphorylation and subsequent activation,
particularly in situations of cellular stress and phagocytic NOX
activation (Bey et al., 2004; Jiang et al., 2011). The p47-
phox subunit is a particular target of PKC and has been
found to be phosphorylated with pure PKC lysate but not
in mutated versions from patients with autosomal chronic
granulomatous disease (CGD) (Kramer et al., 1988). PMA
(phorbol 12-myristate 13-acetate), a potent PKC activator,
has been shown to induce a respiratory burst of ROS
generation by NOX through the stimulation of PKC (Cox
et al., 1985). This behavior is the foundation for subsequent
studies of NOX activation as well. Furthermore, inhibiting PKC
activation, both broadly with staurosporine in PMA-stimulated
cells and specifically with PKC-δ inhibitors, prevented NOX
activation and ROS generation (Nauseef et al., 1991; Bey et al.,
2004).
As most NOX subunits require phosphorylation to become
activated and complex together, the targeting of PKC to
the p47-phox subunit has been demonstrated as well. The
key serine residues for activation on p47-phox, Ser303, 304
and 328, are residues that are specifically phosphorylated by
PKC isoforms. Staurosporine inhibition of PKC resulted in
p47-phox and p67-phox subunits localized exclusively in the
cytosol and also attenuated p47-phox phosphorylation (Nauseef
et al., 1991). PKC-β and PKC-δ isoforms were specifically
implicated in p47-phox phosphorylation in neutrophils, as both
were co-immunoprecipitated with p47-phox in PMA-treated
cells (Reeves et al., 1999). Moreover, while PKC-δ inhibition
prevented p47-phox phosphorylation and translocation in
monocytes in vitro, PKC-α and PKC-ε inhibition had no effect,
indicating PKC specificity with activation (Bey et al., 2004). PKC,
particularly the α and δ isoforms, was found to additionally
phosphorylate the p22-phox subunit at its Thr147 position to
further promote interaction with p47-phox (Lewis et al., 2010).
Thus, PKC plays a critical role in activation.
PKC’s role in NOX activation extends to upstream stimuli
and pathways that activate PKC itself. Hyperglycemia-stimulated
PKC expression affected NOX production of ROS in the blood
brain barrier. PKC-α and –β isoforms were elevated and resulted
in increased p47-phox phosphorylation and NOX activation
under hyperglycemic conditions with brain microvascular
endothelial cells, astrocytes, and pericytes simulating the blood
brain barrier. Inhibition of the PKC isoforms reduced p47-
phox phosphorylation accordingly (Shao and Bayraktutan,
2013). In hyperglycemic stimulation of PKC, particularly
PKC-β1, NOX activation was found to potentiate blood
brain barrier breakdown and apoptosis. Such states are
common in stroke injury (Shao and Bayraktutan, 2013,
2014).
Other upstream pathways activating PKC and subsequently
NOX include those of diabetic nephropathy, where advanced
glycation end products (AGEs) or advanced oxidation protein
products (AOPPs) increased PKC activity, particularly of PKC-α,
with resulting increases in NOX (Williams, 2007; Thallas-
Bonke et al., 2008; Wei et al., 2009). The PKC-α inhibitor
Ro-32-0432 reduced superoxide production andNOX activation,
demonstrating PKC’s role in activating NOX (Thallas-Bonke
et al., 2008; Wei et al., 2009). Moreover, the angiotensin
II (ANGII) axis of ROS production via endothelial NOX
similarly implicates PKC. ANGII significantly increased p47-
phox phosphorylation, increased p47-phox interaction with
p22-phox, and subsequent increased superoxide production
(Landmesser et al., 2002; Li and Shah, 2003). In vascular smooth
muscle cells, ANGII increased PKC-δ association with p47-phox
and p47-phox translocation to the membrane, inducing ROS
production via an ANGII/PKC-δ/p47-phox pathway of NOX
activation (Lv et al., 2012).
Thus, PKC plays an essential role in activating NOX and
PKC itself is activated by several upstream stimuli to facilitate
NOX activation. Interestingly, different PKC isoforms act as the
main NOX activator in different tissues. PKC-δ is the dominant
isoform in leukocytes, associated particularly with NOX2. PKC-β
also played a role, but PKC-α did not act in leukocytes (Reeves
et al., 1999; Bey et al., 2004). However, PKC-α appears to have
a large role in NOX activation in the kidney, where NOX2 and
NOX4 dominate. Alternate NOX isoforms may account for the
difference in activating PKC isoforms across studies, though
definitive preference or association between PKC and NOX
isoforms is not yet clear. Moreover, different instigating stimuli,
such as hyperglycemia, AGEs, and ANGII, may also affect
different PKC isoforms and cause the subsequently observed
differences in NOX activation across different PKC isoforms.
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Elucidating which isoforms are dominant in neurological
conditions requires further study, though the inflammatory
pathology behind many diseases suggests a larger role of PKC δ
and PKC-β.
Lastly, arachidonic acid was found to act synergistically
with PKC activation of NOX to increase activation, especially
by potentiating the p47-phox binding to p22-phox. It likely
functions through disrupting the p47-phox SH3 masking
by the polybasic C-terminal region in conjunction with
phosphorylation of Ser residues by PKC (Shiose and Sumimoto,
2000). Overall, PKC plays a crucial role in phosphorylation of
NOX subunits. This suggests that there is therapeutic potential
in manipulating NOX activation through modulating upstream
PKC pathways in pathologic states. However, to achieve this
therapeutic goal, more specificity regarding the action of specific
PKC isoforms and how they affect specific NOX isoforms must
be determined.
Interactions of p47-phox and p22-phox
NOX activation is heavily modulated, especially through protein-
protein interactions. The cytosolic subunits complex through
such interactions and subsequently translocate to the membrane
subunits to activate the catalytic core of gp91-phox (Sumimoto,
2008). One key protein-protein interaction is the binding of
p47-phox to p22-phox during translocation, to anchor the
complex of cytosolic subunits to the membrane and provide the
correct enzyme configuration for activation (Sumimoto, 2008).
As mentioned, this is facilitated by the interaction between the
SH3 domains of p47-phox and the proline rich regions of p22-
phox. Unmasking the SH3 domain is necessary to this interaction
and is facilitated by phosphorylation, most commonly through
the PKC isoforms as previously explained (Groemping and
Rittinger, 2005). In the activated NOX complex, the p47-
phox subunit is the most phosphorylated subunit. Thus far,
11 phosphorylation sites have been identified: serine residues
303, 304, 310, 315, 320, 328, 345, 348, 359, 370, and 379 (Faust
et al., 1995).
Only the most phosphorylated p47-phox subunits translocate
to the membrane, but the residues themselves have been found
to play different roles in the process. An initial study found
that independent phosphorylation of Ser379 is necessary for
p47-phox translocation (Faust et al., 1995). It was also found
that the residues at Ser359 and Ser370 were necessary in
facilitating phosphorylation of subsequent residues, allowing
translocation and enabling oxidase activity (Johnson et al.,
1998). However, these three residues (Ser379, Ser359 and
Ser370) are not sufficient to interact with the p22-phox subunit.
These residues are also located outside the region interacting
with the SH3 domains, from 286 to 340 (Ago et al., 1999).
Thus, the Ser359 and Ser370 residues are likely involved in
separate aspects of translocation and NOX activation, likely
supporting superoxide production rather than unmasking the
SH3 domain (Johnson et al., 1998; Ago et al., 1999). Instead,
simultaneous phosphorylation of only Ser303, Ser304, and
Ser328 was found to be sufficient in inducing the conformational
change needed to reveal the SH3 domains for p22-phox (Ago
et al., 1999). As a result, Ser303, Ser304, and Ser328 are
the key serines on p47-phox that facilitate targeting of the
cytosolic subunits to the membrane at p22-phox for proper NOX
assembly.
NOXO1 (NOX organizer 1) further demonstrates the
functionality of the p47-phox subunit. It encodes for a homolog
of p47-phox and conserves the main interactive domains
of p47-phox but lacks the polybasic region that masks the
SH3 domains in p47-phox. Thus, it is constitutively active
and able to bind p22-phox without phosphorylation. Moreover,
superoxide production in cells transfected with NOXO1 was
elevated compared to those with p47-phox in the absence of any
stimulants, demonstrating that the unmasking of SH3 domains
is key in organizing and activating NOX. Moreover, this explains
the constitutive activity of NOX1, as it is commonly found with
NOXO1 (Takeya et al., 2003).
Once exposed, the SH3 domain binds to the proline rich
region of p22-phox, which anchors the cytosolic p47-p67-
p40 complex to the membrane complex for activation (Leusen
et al., 1996). Moreover, phosphorylation of the p22-phox subunit
at the Thr147 position is also integral to the p47-phox/p22-
phox interaction. When replaced with alanine, NOX activity was
reduced significantly and phosphorylation of p22-phox by the
PKC-α and –δ isoforms was prevented altogether (Lewis et al.,
2010). Thus, this interaction is key to the recruitment of cytosolic
subunits and NOX function.
The importance of the proline rich region in p47-phox
and p22-phox interaction has been demonstrated clinically in
a patient with CGD who had a single mutation of proline to
glutamine at residue 156 of p22-phox. p47-phox translocation
and association with the membrane was nearly absent in cells
stimulated with PMA. The recruitment of p67-phoxwas similarly
absent in this patient’s cells without p47-phox to organize it.
Dysfunction of NOX in the patient resulted from the lack of
activation as the catalytic b558 unit functioned normally (Leusen
et al., 1994a).
For further membrane stabilization, p47-phox also has a
PX (phox) domain which binds phosphoinositides in the
membrane. This domain is similarly masked by interactions
with the SH3 domains internal to p47-phox and unmasked by
phosphorylation, crucial for targeting to the membrane (Ago
et al., 2003). p47-phox also hasmultiple binding sites on the gp91-
phox subunit for further NOX complex stabilization, located
along the C-terminal tail of gp91-phox as well as on sites more
N terminal in the peptide. The region around 500 of gp91-phox
is clinically critical. A patient suffering from CGD had an Asp
to Gly mutation at residue 500 and subsequent p47-phox and
p67-phox recruitment to the membrane fraction was strongly
disrupted due to disruption of p47-phox binding at the gp91-
phox region (Leusen et al., 1994b). Thus, these binding sites play
additional supplementary roles in p47-phox translocation to the
flavocytochrome b558.
Once bound, the p47-phox subunit permits for electron
transfers to proceed from the FAD to the heme groups in
flavocytochrome b558 in order to reach oxygen (DeLeo et al.,
1995). The initial transfer from NADPH to FAD only requires
the p67-phox isoform, the activator subunit (Leusen et al.,
1996).
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NOX IN DISEASE
An attractive target for therapeutic inhibition, NOX has been
greatly implicated in varied disease processes. Interestingly, it has
been upregulated and/or activated in several pathological states
such as hyperglycemia, inflammation, cancer, and vascular cases.
This review will focus on its role in neurological diseases. A
summary of these effects are provided in Table 1.
Neurodegenerative Diseases
A particular field of interest is targeting NOX in the CNS as
it is implicated in numerous diseases of the CNS and acts as
its main contributor of ROS. Through its inflammatory actions
and oxidative stress, it is also involved in neurodegenerative
diseases such as Alzheimer’s disease (AD) and Parkinson’s
Disease (PD). Moreover, NMDA receptor activation leads to
superoxide production, primarily via NOX. Thus, sustained
NMDA activation can lead to NMDA excitotoxicity, mediated
by NOX-induced ROS overproduction. As a core mechanism of
several neurodegenerative diseases as well as stroke, this aspect
adds to the potential protection of NOX inhibition (Brennan
et al., 2009).
With differing isoforms present in all neuronal and glial
cells, NOX plays a role in exacerbating AD presentation by
worsening the effects of neurofibrillary tangles and β-amyloid
plaques, though they develop without NOX involvement (Sorce
and Krause, 2009). Beta-amyloid plaques have been found to
activate NOX in astrocytes and microglia, with the cytosolic p47-
phox fraction migrating to the membrane (Bianca et al., 1999;
Shimohama et al., 2000; Abramov et al., 2004; Qin et al., 2006).
NOX inhibition of a neuron-astrocyte culture and a neuron-
microglia culture was found to protect against neuronal cell
damage, implicating both cell types in AD pathology (Abramov
et al., 2004; Qin et al., 2006). Thus, the plaques themselves lead
to the production of toxic ROS and exacerbate both neuronal
death and the symptomatic presentation and progression of
AD. AD animal models deficient in NOX2 were protected
against damage caused by beta-amyloid and did not develop
oxidative stress, cerebral dysfunction or behavior deficits of
AD (Park et al., 2008). Thus, NOX activation secondary to
disease development can exacerbate the disease, providing a
potential pathway to mitigate AD progression through NOX
inhibition.
Though the etiology of PD is still relatively unclear, oxidative
stress and neuroinflammation have been strongly implicated in
PD’s loss of dopaminergic cells. This, in part, has been attributed
to microglial NOX ROS production and cell damage (Hirsch
and Hunot, 2009). Several in vitro and in vivo models have
demonstrated the role of NOX in PD development. In genetic
PD in vitro and in vivo models with knockdown/knockout
PINK1, increases in ROS from both mitochondrial and NOX
sources were observed, with both the nonspecific NOX inhibitor
TABLE 1 | This table summarizes the involvement of nicotinamide adenine dinucleotide phosphate (NAPDH) oxidase (NOX) in the various disease states
discussed in the article and the pathologic effect mediated by NOX.
Disease NOX involvement Pathologic effect Reference
Alzheimer’s
Disease
Beta amyloid-induced activation of NOX ROS
production
NMDA excitotoxicity mediated via NOX ROS
Primarily NOX2 studied
Neuronal cell damage/death, secondary to
amyloid plaques
Cerebral dysfunction and behavior deficits
Bianca et al. (1999); Shimohama et al. (2000);
Abramov et al. (2004); Qin et al. (2006); Xia et al.
(2007); Park et al. (2008); Ushio-Fukai and
Nakamura (2008); Brennan et al. (2009); Kamata
(2009); Sorce and Krause (2009); Costa et al.
(2014) and Yan et al. (2015)
Parkinson’s
Disease
Microglial NOX ROS production and cell damage
Alpha-synuclein mediated NOX activation
NMDA excitotoxicity (mediated via NOX ROS)
ANGII mediated NOX4 activation
NOX1, NOX2, and NOX4 identified but without
distinguishing priority
Dopaminergic neuronal cell loss
Alpha-synuclein aggregation
Motor abnormalities
Microglial activation
Gandhi et al. (2009); Hirsch and Hunot (2009);
Sorce and Krause (2009); Zawada et al. (2011);
Choi et al. (2012); Zawada et al. (2015); Sharma
and Nehru (2016) and Sharma et al. (2016)
TBI NOX-induced ROS overproduction
NMDA excitotoxicity (mediated via NOX ROS)
NOX2 > NOX4
Oxidative stress and secondary brain
damage
Neuroinflammation
Dohi et al. (2010); Cooney et al. (2013); Lu et al.
(2014) and Niesman et al. (2014)
Ischemia Microglial NOX activation secondary to
inflammation/cytokines
Hyperglycemia/PKC pathway of NOX activation and
MMP induction
NOX2 > NOX4 > other NOX isoforms
Hyperglycemia/PKC/NOX activation
ROS mediated direct cell/membrane
damage
Blood Brain Barrier breakdown:
Endothelial apoptosis
MMP-induced tight junction dysfunction
Increased reperfusion injury and infarct size
Increased hemorrhage with t-PA reperfusion
Kleinschnitz et al. (2010); Chen et al. (2011); Tang
et al. (2011); Won et al. (2011); Woodfin et al.
(2011); Tang et al. (2012); Kochanski et al. (2013);
Shao and Bayraktutan (2013, 2014) and Shen et al.
(2016)
ALS NOX-induced ROS overproduction and protein
oxidation
Mutant SOD1 binding Rac to active form, increasing
NOX activity
Primarily NOX2 studied
Direct ROS mediated damage and oxidative
stress
Modified IGF1/AKT survival pathways,
causing motor neuron death
Simpson et al. (2003); Wu et al. (2006); Boillée and
Cleveland (2008) and Harraz et al. (2008)
NOX involvement covers the relevant isoforms, if specified, as well as the pathway through which it acts to cause damage. Pathologic effect specifies the resulting
pathology due to NOX invovlement in the disease state.
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DPI and NOX-siRNA reducing cytosolic ROS (Gandhi et al.,
2009). In in vitro rat nigral dopaminergic cells with PD
induced by MPTP toxin injections, elevated levels of NOX2 and
ROS were observed, both mitigated by NOX inhibition or
NOX2 knockdown (Zawada et al., 2011). Similarly NOX1 and
ROS were elevated in in vitro and in vivo PD models induced
by 6-OHDA injections, and NOX inhibition reduced cell
death (Choi et al., 2012). In PD models in rats, apocynin, a
nonspecific NOX inhibitor, was capable of preventing alpha-
synuclein aggregation as well as alpha-synuclein mediated NOX
activation and ROS production (Sharma et al., 2016). Moreover,
NOX inhibition was protective and reduced dopaminergic
neuronal death, motor abnormalities, microglial activation and
subsequent neuroinflammation after PD was induced via LPS
injection into the rat substantia nigra (Sharma and Nehru, 2016;
Sharma et al., 2016). Interestingly, a postmortem examination
of a small sample of human prePD and PD substantia nigra
brain sections suggest that there may be an ANGII/AT1
(ANGII Type 1 receptor)/NOX4 mediated axis of dopaminergic
nigral dysfunction. In the brain samples, nuclear AT1 was
elevated, though the total AT1 decreased, with increasing disease
severity. This accompanied an elevation in NOX4 and caspase-
3, suggesting ANGII-activated NOX4 as a possible pathway of
dopaminergic cell death in clinical PD (Zawada et al., 2015).
Thus, NOX appears to play a key role in both PD development
and progression and is a promising therapeutic target, both
independently and via upstream signaling pathways such as
ANGII.
Traumatic Brain Injury (TBI)
In TBI, multiple mechanisms cause the final injury, of which
oxidative stress and ROS play a pivotal role. NOX acts as a
key producer of ROS in TBI, mediating further injury. Though
NOX1 to NOX4 are found in the brain, NOX2 increased most
after TBI, though an increase in NOX4 was also observed
within microglial cells. Moreover, NOX inhibition in TBI models
was found to reduce inflammatory injury as well (Cooney
et al., 2013). Other models have also demonstrated increases
in NOX activity post injury (Lu et al., 2014; Niesman et al.,
2014). In TBI models, increased gp91-phox (NOX2) was also
observed and mice deficient for NOX2 genes were found to have
less ROS and oxidative damage, inflammation and secondary
damage at the site of injury (Dohi et al., 2010). Moreover,
post injury, the brain exhibited NMDA excitotoxicity, which
may cause further NOX activation and damage (Niesman et al.,
2014). As TBI derives from direct injury and the resulting
neuroinflammation responses that occur, the oxidative damage
done is likely due to direct ROS damage from NOX rather
than through signaling pathways. NOX has emerged as one
of the main contributors of ROS in TBI, making it a potent
neuroprotective target.
Stroke
Of CNS disease states, ischemic stroke is one of the most
studied conditions for NOX activity. Stroke-induced increases
in NOX expression, activity, and ROS-mediated damage have
been widely observed post ischemia (Tang et al., 2012; Kochanski
et al., 2013; Shen et al., 2016). As part of stroke pathology,
the lack of blood flow causes injury to mitochondria to the
affected regions of the brain. Once reperfusion occurs, the
influx of oxygen cannot be detoxified by the mitochondria.
As shown in Figure 1, the influx of excess glucose with
reperfusion causes increased production of NADPH via the
hexose monophosphate shunt, using the glycolytic intermediate
glucose 6-phosphate and producing downstream glycolytic
intermediates such as fructose 6-phosphate that go on to enter
the tricarboxylic acid (TCA) cycle and produce adenosine
triphosphate (ATP) in mitochondria. Thus, with plentiful
substrates and a hyperglycemic state, NOX is activated and
generates an increased amount of ROS, resulting in subsequent
injury. The ROS directly damage cells by compromising
membrane integrity via lipid peroxidation and organelle damage.
However, they also cause injury by upregulating several
inflammatory factors and cytokines, including IL-1β, TNF-α,
iNOS, and bradykinin (Chen et al., 2011; Tang et al., 2012).
Moreover, bradykinin and IL-1β activate NOX in order to
cause blood brain barrier breakdown (Woodfin et al., 2011).
NOX2 knockout mice demonstrated reduced inflammation with
a reduced elevation of these inflammatory factors, reduced
microglial activation and overall reduced infarct size, greatly
implicating NOX in both inflammation and infarct progression
(Chen et al., 2011).
A hyperglycemic state has been associated with acute
stroke and hyperglycemia has independently been found to
induce NOX activation as well (Wang et al., 2013; Shao and
Bayraktutan, 2014) Hyperglycemic states have been found to
potentiate blood-brain barrier breakdown through endothelial
apoptosis facilitated by PKC-induced NOX activation of
apoptotic pathways and through tight junction dysfunction
due to NOX-induced MMP induction (Shao and Bayraktutan,
2013, 2014). Rat models have also shown increased blood-brain
barrier permeability and increased infarct and hemorrhage with
t-PA reperfusion in hyperglycemic rat models that was reversed
with NOX inhibition with apocynin (Won et al., 2011). Thus,
hyperglycemia may exacerbate stroke and reperfusion injury.
Moreover, stroke pathogenesis is attributed more to the
NOX (NOX2) of circulating immune cells compared to
the endogenous microglial and neuronal cells, though both
contribute to the stroke pathology (Tang et al., 2011; Kahles and
Brandes, 2013). However, a growing body of evidence shows that
targeting NOX4 is effective as well, with deletion of NOX4 or
targeted inhibition with VAS2870, a NOX4 inhibitor, resulting
in reduced oxidative stress, blood brain barrier disruption,
neuronal death, and mortality (Kleinschnitz et al., 2010). The
prominence of NOX in ischemia/reperfusion pathology is critical
to its understanding and to potential treatment options of the
disease.
Cerebrovascular conditions potentiate the risk of stroke
as well, and these conditions are further mediated by NOX.
ROS increases hypertension and atherosclerosis by inducing
endothelial dysfunction, vascular remodeling and increased
stiffness as well as altering the availability of vasoactive
compounds such as nitric oxide to reduce vasodilation
capabilities (Williams, 2007; Kinkade et al., 2013). Moreover,
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NOX is inextricably linked to the inflammatory response,
which exacerbates atherosclerosis further (Arenillas, 2015). The
isoforms located within blood vessels vary widely, with a
widespread presence of NOX4 as well as NOX1, NOX2 and
NOX5 in different vessel layers (Takac et al., 2012). However
NOX 1 and 2 are the main mediators of vascular damage
(Chrissobolis et al., 2012; Takac et al., 2012; Gray and Jandeleit-
Dahm, 2015). With such increases in vascular damage, increases
in thrombus formation and thromboembolic stroke can increase.
Moreover, atherosclerosis and hypertension are associated risk
factors and potential causative agents for the disease (Ay
et al., 2005; Goldstein et al., 2011). Thus, NOX acts on both
the initial cause of stroke and mediates its injurious effects
afterwards.
Amyotrophic Lateral Sclerosis (ALS)
Neurodegeneration seen in ALS has also been attributed largely
to oxidative stress. In ALS, neurodegeneration of motor neurons
occurs, resulting in muscle weakness, paralysis and death.
Oxidative stress markers, including lipid peroxidation products
malondialdehyde and 4-hydroxynonenal, were elevated in both
patient CSF and serum as well as in animal models of ALS
(Simpson et al., 2003). Moreover, in both sporadic ALS patients
and animal models, NOX2 was elevated, particularly in microglia
in the spinal cord. It was found to mediate protein oxidation,
and particularly, modify IGF1/AKT survival pathways in motor
neurons to facilitate damage (Wu et al., 2006). In familial ALS,
a toxic gain of function mutation in superoxide dismutase 1
(SOD1) is the main cause in 25% of cases. SOD1 regulates
NOX by binding Rac and inhibiting its GTPase activity and
maintaining its active GTP bound form. Normally, it uncouples
from Rac in the presence of H2O2. With the mutation, the
redox uncoupling is defective and leads to increases in Rac/NOX
activity and activation as Rac remains in its active form (Simpson
et al., 2003; Harraz et al., 2008). Moreover, NOX deletion or
treatment with apocynin to inhibit NOX prolonged survival and
reduced neurodegeneration in mice models and glial cells (Wu
et al., 2006; Boillée and Cleveland, 2008; Harraz et al., 2008).
Overall, the pathology of ALS implicates NOX-mediated ROS
production and damage and provides a novel therapeutic target
for the condition.
NOX-Induced ROS Mechanisms in Cellular
Damage
In these disease states, despite normal NOX function acting
through protective or biologically necessary mechanisms, the
pathological and unbalanced ROS production can damage tissue
though multiple pathways. Primarily, it contributes to direct
damage. This damage is through direct ROS damage to lipid
membranes, causing lipid peroxidation breakdown and potential
necrotic death. This can also lead to apoptotic pathway initiation
with the release of cytochrome C from the mitochondrial
membrane, through mitochondrial damage or upregulation of
pro-apoptotic BAX and cause both endothelial and neuronal
cell death (Hampton and Orrenius, 1997; Brieger et al., 2012).
Necrotic death can also ensue, as seen in ischemia/reperfusion
injury. Further damage can be caused through direct damage to
DNA itself, further inducing either apoptosis or carcinogenesis if
the cell cannot repair itself (Brieger et al., 2012). Moreover, ROS
can induce autophagy and at excessive levels cause autophagic
cell death, as seen in nerve growth factor deprived sympathetic
neurons (Scherz-Shouval and Elazar, 2007).
However, damage is also done through auxiliary signaling
pathways. In neuronal damage, cell death results from both direct
damage, with ROS and mitochondrial dysfunction, and through
the induced inflammation (Lambeth, 2007). ROS can upregulate
the production of toxic factors, such as IL-1, TNF-α and more
superoxide causing neurodegeneration (Block and Hong, 2005).
Several other pathways are involved in a more disease specific
manner that allow for disease progression outside of simple cell
death, as mentioned in the previous disease states. However,
NOX overproduction of ROS seen in pathology can be very
cytotoxic through numerous mechanisms.
POTENTIAL TREATMENTS ON NOX
ACTIVATION
NOX inhibition through therapy and targeted drugs has great
potential for mitigating disease progression, especially given
the widespread involvement of NOX in various disease states.
However, targeting NOX specifically is a goal in therapy,
given the different roles, particularly in immunity, that NOX
has physiologically and the different roles each isoform
has in disease. NOX inhibition itself can function through
several pathways: (1) To inhibit upstream activators of NOX;
(2) To interrupt subunit interactions for activation, preventing
assembly; (3) To block the flavocytochrome itself, particularly
targeting gp91-phox (NOX2) or its catalytic homolog; and (4) To
interfere with NOX activity through indirect pathways. However,
in many cases, the mechanism of inhibition is unclear or acts
on a transcriptional/translational level prior to activation. A
general summary of the inhibitors’ location of action is shown
in Figure 1.
A General Inhibition of NOX Action
Several therapeutic interventions are available, include
normobaric oxygen (NBO), hyperbaric oxygen (HBO), and
hibernation therapy, which inhibit NOX via unspecified
mechanisms (Figure 1¬). In the cases of NBO and HBO,
there is the contradicting thought that increased oxygen would
exacerbate NOX-mediated ROS production. However, both
NBO and HBO have been found to be paradoxically protective
in cases of stroke without contributing to further oxidative
stress (Singhal et al., 2002; Schäbitz et al., 2004). In one study,
NBO reduced blood brain barrier disruption through reduced
levels of NOX2 and NOX-induced MMP-9 while preventing
occludin degradation in cerebral ischemia (Liu et al., 2011). HBO
also downregulated NOX2 expression and NOX activity and
improved functional outcome and neuronal survival due to the
decrease in oxidative stress in a subarachnoid hemorrhage
model (Ostrowski et al., 2006). Hibernation therapies,
such as hypothermia or drug-induced hibernation such as
ethanol, are also protective in stroke (Kim and Yenari, 2015;
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Forreider et al., 2016). Of these, ethanol, by itself and in
conjunction with NBO, has been shown to decrease NOX
levels and activity in a model of ischemic stroke. It likely acts
through an upstream mechanism involving PKC and AKT. It
also exhibited reductions in infarct volume, neurological deficit,
and ROS levels in a stroke model (Kochanski et al., 2013; Cai
et al., 2016). These broad therapies however lack specificity in
NOX action and act on multiple levels.
VAS2870 (Vasopharm), 3-benzyl-7-(2-benzoxazolyl)thio-1,
2,3-triazolo[4, 5-d]pyrimidine, is another inhibitor and has been
found to reduce ROS increases in oxidized LDL stimulated
endothelial cells (Stielow et al., 2006). Though its mechanism
of action is not certain, recent studies have implicated NOX2
and NOX4. One study demonstrated a reduction in ROS and
NOX4 expression in skeletal muscle with VAS2870 and
suggested a thiol alkylation and modification mechanism of
NOX4 inhibition (Sun et al., 2012). A more recent study with
a stroke model suggests it acts by upregulation of microRNA
that target NOX2 and NOX4 genes and suppress them in stroke.
VAS2870 was also found to reduce infarct volume in stroke
as well, providing potential for future use (Liu et al., 2016).
While promising, off target effects via thiol alkylation on the
ryanodine receptor-Ca2+ channel were found, eliminating its
activation and potentially causing muscle dysfunction (Sun et al.,
2012).
Inhibition of Upstream Activators of NOX
The first type of inhibitors utilizes upstream targeting of
PKC and PKC activation pathways for NOX inhibition as
a potential therapy (Figure 1­). PKC inhibitors such as
Calphostin C, chelerythrine and ruboxistaurin mesylate (RBX)
have all been shown to reduce hypertension. RBX is currently
in clinical trials for use in diabetic complications, but it has
additional function in NOX inhibition (Williams, 2007). In
several studies, high concentrations of PKC inhibitors have
reduced ischemic damage in vivo or cell death in vitro, though
more work needs to be done to assess its use for ischemia or
neurodegenerative diseases therapeutically (Bright and Mochly-
Rosen, 2005). However, PKC inhibitors lack specificity to NOX
activation, and PKC is implicated in numerous cellular functions
and signaling, creating a potential for varied and severe side
effects. Other upstream targets also have shown potential.
As previously described, ethanol potentially acts through a
PKC/AKT pathway of NOX inhibition (Cai et al., 2016). Total
salivanolic acid injection (TSI), an injection derived from Salvia
miltiorrhiza, is a therapy targeting a PKC activation pathway.
It is currently approved in China for treatment of ischemic
stroke, particularly with thrombolytic therapy. Through its use,
AMPK expression is enhanced, resulting in the subsequent
observed reduction of AKT activation, PKC translocation to
the membrane, and overall NOX activation with the failure
of migration of the cytosolic subunits to the membrane.
It acts via the AMPK/AKT/PKC signaling pathway (Tang
et al., 2014). By defining the pathological upstream activators
of NOX in specific disease states, NOX inhibition can be
facilitated by targeting these upstream players, such as PKC and
ANGII.
NOX Subunit Interactions and their
Therapeutic Perspectives
The second type of NOX inhibitors acts via inhibition of
NOX assembly (Figure 1®). Understanding NOX activation
via p47-phox phosphorylation by PKC isoforms and subsequent
interaction with the p22-phox subunit has opened up new areas
of therapeutic investigation. While many of the inhibitors or
therapies mentioned previously function by inhibiting upstream
NOX activators or through unspecified overall inhibition, greater
specificity can be achieved through targeting therapies at subunit
interactions.
One of the most promising NOX inhibitors is apocynin, or
4-hydrozy-3-methoxy acetophenone, which blocks migration of
p47-phox to the membrane and prevents NOX assembly and
activation. In ischemic injury, it protected against early lipid
peroxidation, neuronal degeneration and death, and glial cell
activation as a pretreatment and, at low doses, was found to be
effective in improving neurological outcomes, reducing infarct
volume and hemorrhage (Wang et al., 2006; Tang et al., 2008).
It was also found to reduce glial death and promote survival in
ALS mice models (Boillée and Cleveland, 2008; Harraz et al.,
2008). However, apocynin acts on NOX1 and 2 more than
NOX4, the constitutively active NOX isoform. It also requires
myeloperoxidase (MPO) for function as it must dimerize to
act on NOX. When acting on NOX4 and in the absence of
MPO, apocynin was found to act as an antioxidant scavenger
(Heumüller et al., 2008). Thus, its scope of use must be more
definitively established.
Another promising drug is gp91-ds-tat, a NOX inhibitor
specific to NOX2, and potentially NOX1 (Williams, 2007). It
functions through inhibition of p47-phox binding to gp91-phox
through emulating the binding region of gp91-phox. As a peptide,
it internalizes via a sequence corresponding to the HIV viral
coat. In mice with AD, it was shown to reduce ROS as well as
cerebrovascular dysfunction that contributes to AD pathology
(Park et al., 2008). It potentially has other cerebrovascular
benefits, as it has been shown to reduce hypertension in ANGII
stimulated models as well (Rey et al., 2001). However, it requires
intravenous injection due to limited oral bioavailability as a
peptide, restricting its clinical potential (Williams, 2007).
While potential pharmaceuticals and their mechanisms are
still being investigated, the uniquely modulated activation
of NOX allows for increased specificity to NOX isoforms
controlled by cytosolic subunits, primarily NOX1–3. Moreover,
understanding the biochemical interactions between subunits
opens the field to finding inhibitors that target sequences
specific to NOX subunits, lowering the widespread side effects
of affecting similar groups on other molecules or upstream
activators that are not specific to NOX.
NOX Flavocytochrome Inhibitors
Certain inhibitors, the third type, target the flavocytochrome
itself to inhibit NOX (Figure 1¯). Of these,
diphenyleneiodonium (DPI) is the most commonly used.
It forms an irreversible redox adduct with reduced FAD of
the NOX catalytic core. Thus, it halts superoxide production
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altogether upon NOX activation through uncompetitive
inhibition (O’Donnell et al., 1993). In conjunction with
dimethylsulfoxide, a free radical scavenger, it was found
to reduce infarct size, blood brain barrier disruption, and
neurological damage in a stroke model (Nagel et al., 2007).
However, its safety is questionable as other flavoenzymes
necessary to metabolism may also be inhibited (O’Donnell et al.,
1993; Tang et al., 2012). More recent inhibitors are focusing on
generating inhibitors specific to NOX isoforms when targeting
the catalytic core. GSK2795039, a small molecular inhibitor,
has been recently developed and was found to be protective
in paw inflammation and acute pancreatitis mouse models.
Unlike DPI, it is specific to NOX2, demonstrating reduction
in NOX2 activity via competitive inhibition with little to no
inhibition of other NOX isoforms and other flavoenzymes,
such as xanthine oxidase or nitric oxide synthase (Hirano
et al., 2015). Given the increasing evidence for NOX2’s role
in such conditions as stroke and the moderate bioavailability
of the drug in the brain, the inhibitor has potential in treating
ischemia and neurodegenerative disorders as well (Kahles and
Brandes, 2013; Hirano et al., 2015). GKT137831 is another such
inhibitor but it is specific to NOX 1/4, allowing for varying
specificity and targeting. It has shown potential in cases of
fibrotic and inflammatory diseases, including liver fibrosis,
pulmonary fibrosis, inflammation, and ischemic retinopathy
(Aoyama et al., 2012; Deliyanti and Wilkinson-Berka, 2015).
Given its role in inflammation and ischemic retinopathy, it
may show potential in cerebrovascular conditions like stroke
and in neurodegenerative diseases where neuroinflammation
plays a core role in the pathology, but further studies need to be
done to investigate its use in neurological diseases. Unlike with
NOX2 inhibition, little immunosuppression is observed and no
spontaneous pathologies are found upon NOX4 inhibition or
deletion (Aoyama et al., 2012). Moreover, it has progressed to
clinical trials, showing great promise (Teixeira et al., 2016).
Indirect NOX Inhibitors
Finally, the fourth type of inhibitors use indirect pathways
of action and include angiotensin converting enzyme
(ACE) inhibitors and angiotensin receptor blockers, which
would function by reducing NOX activation induced by the
ANGII/PKC pathway. Statins also inhibit NOX by preventing
geranylgeranylation, necessary for Rac translocation to NOX
(Figure 1°; Wassmann et al., 2002; Williams, 2007). They
have been shown to reduce ROS production, atherosclerotic
lesion size, and even endothelial dysfunction in mild essential
hypertension in a small human study (Williams, 2007). Though
they have not been studied with regard to neurological diseases,
they play an important role through reducing cerebrovascular
complications that may ensue from such conditions, including
stroke.
CONCLUSION AND PROSPECTIVE
STUDIES
NOX plays a detrimental role in a widespread range of diseases
through its overproduction of ROS, which then damage tissue
directly and initiate deleterious signaling cascades within the
body. Thus, NOX inhibition has great potential as a therapeutic
treatment that can act across several disease states. The potential
for further refinement of NOX inhibition is in understanding
the key role of p47-phox and its translocation to the membrane
subunit p22-phox via phosphorylation by PKC. The p47-
phox subunit SH3 domains are masked at rest, and through
serine phosphorylation by PKC isoforms at multiple sites, the
polybasic masking domain changes conformation to allow for
the SH3 domains of p47-phox to interact with the proline
rich region of p22-phox. It translocates to the membrane to
anchor the other cytosolic subunits to the membrane catalytic
core and facilitate NOX activation. Through understanding this
process, the potential of NOX inhibitors of NOX assembly,
function, and upstream activation, as a clinical therapy for
neurological, vascular, and metabolic conditions has been
unveiled. Particularly, NOX activation can be prevented through
the inhibition of subunit assembly by, surprisingly, blocking
the interaction between two key subunits, p47-phox and p22-
phox. Further research into finding new potential inhibitors
and enhancement of the current ones is still necessary, but
investigation into inhibitors of NOX assembly allows for a unique
avenue of exploration.
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